Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1170 Results for "
humanized
" in MedChemExpress (MCE) Product Catalog:
Products (1170)
1170 Results for "humanized" in MCE Product Catalog:
76
76 Publications Verification
Cat. No.: HY-P9907
CAS No.: 180288-69-1
Synonyms: Anti-Human HER2, humanized Antibody
Research Areas:
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
76
76 Publications Verification
Cat. No.: HY-P9907A
CAS No.: 180288-69-1
Synonyms: Anti-Human HER2, humanized Antibody (anti-HER2)
Target:
Research Areas:
66
66 Cited Publications
Cat. No.: HY-P9906
CAS No.: 216974-75-3
Synonyms: Anti-Human VEGF, humanized Antibody
Target:
Research Areas:
Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer .
66
66 Cited Publications
Cat. No.: HY-P9906A
CAS No.: 216974-75-3
Target:
Research Areas:
Bevacizumab (Anti-VEGFA) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab (Anti-VEGFA) blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab (Anti-VEGFA) possesses immunomodulatory properties. Bevacizumab (Anti-VEGFA) can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer .
51
51 Cited Publications
Cat. No.: HY-P9917
CAS No.: 375823-41-9
Synonyms: Anti-Human IL6R, humanized Antibody; RG-1569; rhPM-1
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
43
43 Cited Publications
Cat. No.: HY-P9904
CAS No.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267
Target:
Research Areas:
37
Target:
Research Areas:
37
Target:
Research Areas:
16
16 Cited Publications
Target:
Research Areas:
NF-56-EJ40 is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
16
16 Cited Publications
Cat. No.: HY-130246A
CAS No.: 2728500-80-7
Target:
Research Areas:
NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
14
14 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Target:
Research Areas:
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
14
14 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
Target:
Research Areas:
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Note: The product sizes indicate only the active ingredient of ADC. For information about the excipients in this product, please refer to the COA.
14
14 Cited Publications
Cat. No.: HY-P99003
Target:
Research Areas:
13
13 Cited Publications
Cat. No.: HY-P9912
CAS No.: 380610-27-5
13
13 Cited Publications
Cat. No.: HY-P9912A
CAS No.: 380610-27-5
10
Target:
Research Areas:
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
8
Target:
Research Areas:
7
6
Target:
Research Areas:
Palivizumab (MEDI-493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
6
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
